BEX1

BEX1 is a small intrinsically disordered adaptor protein that operates as a context-dependent signaling modulator across neuronal differentiation, apoptosis, innate immunity, ciliogenesis, and cancer stem-cell biology (PMID:16498402, PMID:24626299, PMID:29192139, PMID:35144600). In the nervous system it binds the intracellular domain of the p75 neurotrophin receptor in competition with RIP2, and through this node it suppresses NGF-induced NF-κB activation, sustains proliferation, and restrains neuronal differentiation in a cell-cycle-coupled manner (PMID:16498402). At the mitochondrion, BEX1 localizes via a defined internal segment and interacts with BCL-2 to disrupt anti-apoptotic BCL-2/BAX heterodimers, thereby promoting apoptosis (PMID:24626299). As an intrinsically disordered protein, BEX1 forms biomolecular condensates, binds GTP, and facilitates tubulin polymerization at the basal body, an activity required for primary cilium formation, since its loss produces ciliopathy phenotypes in mice (PMID:35144600). In cardiomyocytes BEX1 associates with a large ribonucleoprotein complex to stabilize AU-rich-element-containing proinflammatory mRNAs and to control IFN-β-mediated antiviral defense, where it limits replication of multiple viruses but worsens stress-induced heart failure (PMID:29192139, PMID:35192678). In liver cancer BEX1 suppresses PPARγ to drive a PDK1-dependent Warburg effect and progenitor expansion, and binds RUNX3 to relieve β-catenin repression and activate Wnt/β-catenin-dependent stemness (PMID:29907129, PMID:34217777, PMID:37715024). BEX1 expression is repressed by promoter DNA methylation, including DNMT1- and EZH2/LINC00630-mediated silencing, linking its loss to tumor suppression in several contexts (PMID:16818640, PMID:32119177, PMID:34217777).

1. 2006 Medium

   Established BEX1's first molecular function by placing it at the p75 neurotrophin receptor, defining how it gates neuronal differentiation versus proliferation.

   Evidence Interactor screening, competition binding with RIP2, and gain/loss-of-function with NF-κB reporters in PC12 cells

   PMID:16498402

   Open questions at the time

   • Binding site on the p75NTR intracellular domain not mapped
   • Mechanism by which RIP2 competition feeds NF-κB output not resolved at molecular detail
2. 2006 Medium

   Connected BEX1 silencing to tumor biology, showing epigenetic loss of BEX1 contributes to malignancy and chemoresistance.

   Evidence Viral re-expression, chemotherapy apoptosis assays, xenografts, and pharmacological demethylation/HDAC unmasking in glioma

   PMID:16818640

   Open questions at the time

   • Direct molecular effectors downstream of BEX1 in glioma not defined here
   • Relationship between tumor-suppressor role and p75NTR signaling not addressed
3. 2007 Medium

   Extended BEX1 function beyond neurons by linking it to calcium signaling and tissue regeneration kinetics.

   Evidence Calcium-dependent calmodulin binding assay and Bex1 KO mouse skeletal muscle regeneration phenotyping

   PMID:17884015

   Open questions at the time

   • Functional consequence of calmodulin binding for BEX1 activity unclear
   • Link between CaM interaction and the regeneration phenotype not established
4. 2010 Medium

   Demonstrated a pro-regenerative role in peripheral nerve by showing BEX1 antagonizes myelin-derived growth inhibition.

   Evidence Sciatic nerve injury in Bex1 KO mice and MAG-mediated axon outgrowth inhibition assays

   PMID:20731761

   Open questions at the time

   • Molecular target through which BEX1 antagonizes MAG signaling not identified
   • Relation to its p75NTR interaction not tested
5. 2014 High

   Defined a mitochondrial apoptotic function, showing BEX1 acts on the BCL-2/BAX rheostat.

   Evidence Yeast two-hybrid, reciprocal Co-IP, mitochondrial-targeting deletion mutagenesis, and imatinib apoptosis assays

   PMID:24626299

   Open questions at the time

   • Structural basis of BEX1–BCL-2 binding not solved
   • Whether BEX1 directly competes for the BAX-binding interface not shown
6. 2015 Medium

   Showed cell-type-specific signaling effects, with BEX1 suppressing FLT3-ITD-driven proliferation selectively through AKT.

   Evidence Overexpression in pro-B/myeloid cells, colony/xenograft assays, fractionation, and phospho-specific blotting

   PMID:26046670

   Open questions at the time

   • Mechanism by which cytosolic BEX1 dampens AKT phosphorylation unknown
   • Direct binding partner in this context not identified
7. 2015 Medium

   Identified a developmental role in myoblast fusion accompanied by regulated cytoplasm-to-nucleus translocation.

   Evidence Immunofluorescence localization plus overexpression and KO myoblast fusion assays

   PMID:26586200

   Open questions at the time

   • Signal driving nuclear translocation not defined
   • Molecular mediators of the fusion phenotype unidentified
8. 2017 High

   Revealed an RNA-regulatory function, placing BEX1 in a ribonucleoprotein complex that stabilizes proinflammatory ARE mRNAs in the failing heart.

   Evidence Proteomic complex identification, mRNA stability assays, and reciprocal cardiac transgenic and gene-deleted mouse models under stress

   PMID:29192139

   Open questions at the time

   • Direct RNA-binding vs adaptor role within the RNP not distinguished
   • Other components of the BEX1-associated RNP not fully enumerated
9. 2018 Medium

   Established a metabolic/progenitor role through PPARγ suppression driving liver progenitor cell expansion.

   Evidence Bex1 KO mice on CDE diet, PPARγ-silencing epistasis, and LPC proliferation/apoptosis assays

   PMID:29907129

   Open questions at the time

   • Mechanism linking BEX1 to PPARγ repression not molecularly defined
   • Whether suppression is transcriptional or post-translational unknown
10. 2020 Medium

    Clarified an epigenetic silencing route, showing EZH2/LINC00630 represses BEX1 to confer radioresistance.

    Evidence RIP, ChIP, shRNA knockdown, and viability/apoptosis rescue by BEX1 silencing in irradiated colorectal cancer cells

    PMID:32119177

    Open questions at the time

    • Direct BEX1 effectors mediating radiosensitivity not identified
    • Context-specificity of this silencing axis untested across tumor types
11. 2021 Medium

    Connected BEX1 to Wnt/β-catenin-driven cancer stemness via RUNX3, and tied its expression to DNMT1 methylation in liver cancer.

    Evidence Co-IP, sphere formation, Wnt reporter assays, xenografts, and DNMT1 inhibitor treatment

    PMID:34217777

    Open questions at the time

    • RUNX3-binding interface on BEX1 not mapped
    • How BEX1 relieves RUNX3 repression of β-catenin mechanistically unresolved
12. 2021 Low

    Proposed a cytoskeletal/mechanotransduction role in glioma radioresistance through actin polymerization and YAP/TAZ.

    Evidence Transcriptomics, orthotopic xenografts, actin polymerization and YAP/TAZ assays with latrunculin B

    PMID:34576008

    Open questions at the time

    • BEX1-specific contribution not separated from BEX4
    • Direct effect of BEX1 on actin dynamics not biochemically isolated
13. 2022 High

    Defined BEX1 as an intrinsically disordered, condensate-forming, GTP-binding protein essential for primary ciliogenesis.

    Evidence Biophysical IDP characterization, condensate imaging, GTP-binding and in vitro tubulin polymerization reconstitution, and Bex1 KO ciliopathy phenotyping

    PMID:35144600

    Open questions at the time

    • Structural determinants of GTP binding not defined
    • How condensate formation couples to tubulin polymerization mechanistically unclear
14. 2022 High

    Established BEX1 as an antiviral and IFN-β regulator in cardiomyocytes, integrating its RNP function with innate immune defense.

    Evidence Reciprocal transgenic/KO mice, CVB3 infection, viral load and IFN-β measurement, and replication across influenza A and Sendai virus in isolated cells

    PMID:35192678

    Open questions at the time

    • Direct molecular link between BEX1 and IFN-β induction not defined
    • Whether antiviral effect depends on the ARE-mRNA-stabilizing RNP role untested
15. 2023 Medium

    Resolved the metabolic mechanism in hepatoblastoma, ordering BEX1→PPARγ suppression→PDK1→Warburg effect→stemness.

    Evidence Seahorse flux analysis, LC-MS metabolomics, sphere/xenograft assays, and PPARγ agonist treatment

    PMID:37715024

    Open questions at the time

    • Direct molecular mechanism of PPARγ downregulation by BEX1 still undefined
    • Generalizability beyond hepatoblastoma untested
16. 2025 Low

    Linked BEX1 promoter methylation in glioma to AKT/ERK/STAT3 signaling control of cell cycle and apoptosis.

    Evidence Western blot, qRT-PCR, transfection, and AKT/ERK/STAT3 inhibitors with cell cycle/apoptosis assays

    PMID:40804095

    Open questions at the time

    • No in vivo confirmation reported
    • Direct effectors connecting BEX1 to the three kinase cascades not identified

• It remains unresolved how a single small disordered protein selects among its many reported partners (p75NTR, BCL-2, calmodulin, RUNX3, tubulin, the cardiac RNP) in a given cellular context, and whether condensate formation is the common organizing principle linking these activities.
• No structural model of partner discrimination
• No unifying biochemical mechanism connecting the distinct functional nodes